About Moni HorovitzThis author has not yet filled in any details.
So far Moni Horovitz has created 30 blog entries.
Avraham Pharmaceuticals Closes an Additional Investment Round of Approximately $6 Million by Yissum, Pontifax and Clal Biotechnology Industries
The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim
Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment for Metastatic Pancreatic Cancer
White Plains Hospital is the first U.S. site
to offer this innovative treatment to cancer patients
Integra Holdings closes U.S. $ 7.0 million private financing
Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI
Enrollment has been completed in a Phase 2 study of ladostigil for the treatment of Alzheimer's Disease and results expected in Q4 2012
Jerusalem Israel - February 13, 2012 - Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.
Yissum, Pontifax, Clal Biotechnology Industries, TRDF and Other Investors Complete Additional Investment Round of $3 Million in Avraham Pharmaceuticals
Yissum will now maintain 30% holding share in Avraham Pharmaceuticals, which will be transferred to its forthcoming biotech holdings company
Atox Bio raises $2.1 Million to advance development of AB103, a novel therapy for the treatment of severe bacterial infections.
Rehovot Israel - October 13, 2010 - Atox Bio Inc. today announced that it has raised $2.1 million to advance the development of AB103, a clinical stage therapeutic being developed for the treatment of severe bacterial infections and sepsis.
Atox Bio, a Spin-Off of Yissum, Announces Dosing of First Subject in Phase 1 study of AB103, a Novel Immunomodulator for the Treatment of Severe Bacterial Infections and Sepsis
Rehovot Israel - September 15, 2010 - Atox Bio, a Spin-Off of Yissum, today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103